Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CTSS | P25774 | 2/20 | 0.49 |
| ▸ | CTSK | P43235 | 2/20 | 0.49 |
| ▸ | KLK7 | P49862 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TLR2 | O60603 | 1/20 | 0.37 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7565337 | 0.88 | CTSS (0.53) | TSHRCTSSCTSKKLK7EPHX2 | |
| SCHEMBL5144894 | 0.81 | TSHR (0.64) | TSHRCTSSCTSKPOLBMEN1 | |
| SCHEMBL27483577 | 0.79 | CTSK (0.64) | TSHRCTSSCTSKKLK7EPHX2 | |
| SCHEMBL27704332 | 0.79 | CTSK (0.64) | TSHRCTSSCTSKKLK7EPHX2 | |
| SCHEMBL27688713 | 0.79 | CTSK (0.64) | TSHRCTSSCTSKKLK7EPHX2 | |
| SCHEMBL5142544 | 0.78 | TSHR (0.59) | TSHRCTSSCTSKKLK7POLB | |
| SCHEMBL294929 | 0.77 | CTSS (0.63) | TSHRCTSSCTSKKLK7EPHX2 | |
| SCHEMBL478758 | 0.77 | CTSS (0.63) | TSHRCTSSCTSKKLK7EPHX2 | |
| SCHEMBL14301283 | 0.77 | CTSS (0.63) | TSHRCTSSCTSKKLK7EPHX2 | |
| Hydrochloric Acid SCHEMBL27704331 | 0.77 | CTSK (0.63) | TSHRCTSSCTSKKLK7EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030220495-A1 | Inhibitors of farnesyl protein transferase | ZENECA LIMITED AND ZENECA PHARMA S.A. | 2003-11-27 | — | — | US | disclosed |
| US-6414145-B1 | TREATING CANCER AND NEUROFIBROMATOSIS | ZENECA LIMITED (GB) | 2002-07-02 | — | — | US | disclosed |
| US-6410539-B1 | ANTICARCINOGENIC AGENTS | ASTRAZENCA UK LIMITED (GB) | 2002-06-25 | — | — | US | disclosed |
| EP-1025089-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | ZENECA LIMITED (GB) | 2000-08-09 | — | — | EP | disclosed |
| EP-0975603-A1 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | ZENECA LIMITED (GB) | 2000-02-02 | — | — | EP | disclosed |
| WO-1999020612-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | ASTRAZENECA UK LIMITED (GB) | 1999-04-29 | — | — | WO | disclosed |
| WO-1998032741-A1 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | ZENECA LIMITED (GB) | 1998-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220495-A1 | Inhibitors of farnesyl protein transferase | KRAS, FNTA, FNTB | TSHR 2392/4885CTSS 2820/4885CTSK 3629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.